EG110A

Small molecule

EEG 427

EG110A is one of 44 small molecule programs targeting Spinal Cord Injury. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Spinal Cord InjuryActive, not recruiting

Spinal Cord InjuryPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

190 competitors in Spinal Cord Injury

#DrugCompanyPhaseTrials

Medrol

Pfizer

Phase 3

3 2

Proamatine

Takeda

Phase 3

2 3

Minocin

TTriax

Phase 3

2 4

Actonel

VVitae Pharmaceuticals Inc., an Allergan affiliate

Phase 3

2 5

Deltavit

HHyundai Pharmaceutical Co., LTD.

Phase 3

1 6

Cesamet

BBausch Health Americas, Inc.

Phase 3

1 7

Genotropin

Myrbetriq

2 9

Gleevec

Novartis

Phase 2

1 10

Fampridine-SR

AAcorda Therapeutics

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1/2Recruiting

Spinal Cord Injury

NCT06596291

Q2 2031

Phase 1/2Not yet recruiting

Herpes Simplex Virus

NCT07227285

Clinical

Trials by Indication[1]

Herpes Simplex Virus1 trial

Long-term Follow-up Study of Patients Who Received EG110A, a Non-replicative Herpes Simplex Virus 1-derived Gene Therapy

Not yet recruiting·EEG 427·Phase 1/2·NCT07227285·16 enrolled

Spinal Cord Injury1 trial

Dose Escalation Study of EG110A, Administered by Intradetrusor Injections to Adults With Neurogenic Detrusor Overactivity-related Incontinence Following Spinal Cord Injury Who Regularly Perform Clean Intermittent Catheterization

Recruiting·EEG 427·Phase 1/2·NCT06596291·16 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for EG110A. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — EG110A compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for EG110A. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — EG 427 company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: EEG 427

EG110A

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q2 2031

Trials by Indication[1]

Herpes Simplex Virus1 trial

Spinal Cord Injury1 trial

References

Drug Info

Quick Facts

Related News